Allogeneic hematopoietic stem cell transplantation (HSCT) offers the opportunity for cure among patients with various hematologic malignancies.1 However, until the mid-1990s, allogeneic HSCT had only been offered to relatively young, otherwise healthy patients because it required high-dose chemotherapy and radiation therapy to myeloablate and immune-ablate patients to ensure engraftment.2 Since then, reduced-intensity allogeneic HSCT has been tried, using approximately half the dose of chemotherapy compared with conventional full-intensity allogeneic HSCT.3,4 Reduced-intensity allogeneic HSCT demonstrated that myeloablation was not as necessary as had been thought. This conceptual change created the opportunity to offer allogeneic HSCT to older patients.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 4
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.